- PCMO Operates Exhibition Booth at BIO KOREA 2026

- Preparing for Full Operation of mRNA Manufacturing Facility… Promoting Production Infrastructure

PCMO announced that it participated in BIO KOREA 2026, held from April 28 to 30, where it showcased its mRNA-based biopharmaceutical manufacturing infrastructure and CDMO capabilities.

At the exhibition, PCMO introduced its mRNA drug manufacturing support system and GMP-based production infrastructure through an independent exhibition booth. In particular, the center highlighted its end-to-end CDMO services covering the entire manufacturing process, from Drug Substance (DS) to Drug Product (DP).

PCMO also presented the current status of its mRNA manufacturing facility, which is scheduled to begin full-scale operation in July this year. The center noted that major equipment installation and basic operational preparations have already been completed, and introduced its capability to manufacture and supply pDNA, the starting material for mRNA production.

The newly established mRNA manufacturing facility at PCMO is designed to support both pre-filled syringe (PFS) and vial production. The facility is expected to provide an integrated manufacturing system covering mRNA synthesis, delivery system production, and final drug product manufacturing. Through this infrastructure, PCMO aims to support domestic and international companies across a broad range of stages, from early biopharmaceutical development to clinical and commercial production.

During the exhibition period, the PCMO booth hosted visits and business meetings with representatives from domestic and international pharmaceutical and biotechnology companies. Various opportunities for collaboration were discussed, including mRNA biopharmaceutical manufacturing partnerships and biopharmaceutical process development support.

Jin-Young Song, Head of External Relations Team at PCMO, stated, “Through our participation in BIO KOREA 2026, we were able to introduce PCMO’s mRNA production infrastructure and GMP-based manufacturing capabilities. Moving forward, we will continue to gradually expand our process development support services for domestic and international companies, while strengthening our expertise in quality testing and stability studies for biopharmaceutical production.”